Myriad Genetics, Inc. (NASDAQ:MYGN) enjoyed a 65.77% run-up in share price since hitting record low of $17.50. The stock managed -12.14% fall and now stands at $29.01 as of 03/13/2018. At recent session, the prices were hovering between $28.51 and $30.84. This company shares are 13.24% off its target price of $32.85 and the current market capitalization stands at $2.01B. The recent change has given its price a -17.07% deficit over SMA 50 and -30.21% deficit over its 52-week high. The stock witnessed -11.98% declines, -14.02% declines and -9.63% declines for the 1-month, 3-month and 6-month period, respectively. To measure price-variation, we found MYGN’s volatility during a week at 4.4% and during a month it has been found around 4.19%.Myriad Genetics, Inc. (MYGN) Top Holders
Institutional investors currently hold around $2.47 billion or 0% in MYGN stock. Look at its top three institutional owners. Blackrock Inc. owns $332.4 million in Myriad Genetics, Inc., which represents roughly 16.54% of the company’s market cap and approximately 13.48% of the institutional ownership. Similar statistics are true for the second largest owner, Baillie Gifford & Co, which owns 9,625,846 shares of the stock are valued at $317.85 million. The third largest holder is Vanguard Group Inc, which currently holds $238.55 million worth of this stock and that ownership represents nearly 11.87% of its market capitalization.
At the end of 12/31/2017 reporting period, 144 institutional holders increased their position in Myriad Genetics, Inc. (NASDAQ:MYGN) by some 7,254,590 shares, 103 decreased positions by 7,249,326 and 27 held positions by 60,138,974. That puts total institutional holdings at 74,642,890 shares, according to SEC filings. The stock grabbed 53 new institutional investments totaling 2,237,228 shares while 24 institutional investors sold out their entire positions totaling 2,854,441 shares.Myriad Genetics, Inc. (NASDAQ:MYGN) Insider Trades
Multiple company employees have indulged in significant insider trading. Myriad Genetics, Inc. disclosed in a document filed with the US Securities and Exchange Commission (SEC) that E.V.P., General Counsel Marsh Richard M has sold 37,654 shares of Myriad Genetics, Inc. (MYGN) in trading session dated Jan. 22, 2018. These shares are worth $1,515,574 and were traded at $40.25 each. The SEC filing shows that King Gary A. performed a sale of 34,445 shares. The Exec. VP International Ops disposed these shares by way of transaction on Jan. 22, 2018. The company’s shares were given away at $39.67 per share worth to an income of some $1,366,433 on account of King Gary A..
Exec. VP International Ops, King Gary A., sold 3,120 common shares of Myriad Genetics, Inc. (MYGN) in the open market. In a transaction dated Jan. 18, 2018, the shares were put up for sale at an average price of $38.12, raking in a sum of $118,934. After this sale, 121,968 common shares of MYGN are directly owned by the insider, with total stake valued at $3,538,292.
In the transaction dated Jan. 18, 2018, the great number of shares disposed came courtesy the E.V.P., General Counsel; Marsh Richard M disposed a total of 40,000 shares at an average price of $38.25, amounting to approximately $1,530,000. The insider now directly owns 119,994 shares worth $3,481,026.Myriad Genetics, Inc. (MYGN) Analyst Guide
Several analysts have released their opinion on Myriad Genetics, Inc. (NASDAQ:MYGN), with 3 analysts believing it is a strong buy. Whereas 8 of them predict the stock is a hold. Also, there are 0 buy, 1 sell and 2 strong sell ratings, collectively assigning a 2.88 average brokerage recommendation.